Literatura académica sobre el tema "Eribulin Mesylate"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Eribulin Mesylate".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Eribulin Mesylate"
Huyck, Timothy K., William Gradishar, Fil Manuguid y Peter Kirkpatrick. "Eribulin mesylate". Nature Reviews Drug Discovery 10, n.º 3 (marzo de 2011): 173–74. http://dx.doi.org/10.1038/nrd3389.
Texto completoJain, Sarika y Linda T. Vahdat. "Eribulin Mesylate". Clinical Cancer Research 17, n.º 21 (22 de agosto de 2011): 6615–22. http://dx.doi.org/10.1158/1078-0432.ccr-11-1807.
Texto completoEdwards, Michael S., Dominic A. Solimando y J. Aubrey Waddell. "Eribulin Mesylate and Denosumab". Hospital Pharmacy 46, n.º 4 (abril de 2011): 247–53. http://dx.doi.org/10.1310/hpj4604-247.
Texto completoVerdaguer, Helena, Idoia Morilla y Ander Urruticoechea. "Eribulin Mesylate in Breast Cancer". Women's Health 9, n.º 6 (noviembre de 2013): 517–26. http://dx.doi.org/10.2217/whe.13.61.
Texto completoNieder, Carsten, Gro Aandahl y Astrid Dalhaug. "A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate". Case Reports in Oncological Medicine 2012 (2012): 1–3. http://dx.doi.org/10.1155/2012/537183.
Texto completoBarnato, Sara E., Jacqueline Sara Jeruss, Kevin P. Bethke, Nora M. Hansen, Seema Ahsan Khan, Jamie H. Von Roenn, Steven T. Rosen et al. "Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer." Journal of Clinical Oncology 30, n.º 15_suppl (20 de mayo de 2012): TPS1134. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps1134.
Texto completoPullela, Srinivas Venkata, Vinod Acharya, Nagarjuna Reddy, Jayvant Harlikar, Amar Kulkarni, Rakesh Chavan, Ajay Yadav, Shuvendu Manna y Angshuman Ghosh. "Structural corroboration of two important building blocks of the anticancer drug eribulin mesylate through two-dimensional NMR and single-crystal X-ray diffraction studies". Acta Crystallographica Section C Structural Chemistry 72, n.º 1 (1 de enero de 2016): 14–20. http://dx.doi.org/10.1107/s2053229615022305.
Texto completoNasim, Muhammad Yaser, Ruth Plummer, T. R. Jeffry Evans, Rosemary Morrison, David Alan Anthoney, Sophie Haney, Ayman Madi et al. "A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer." Journal of Clinical Oncology 30, n.º 15_suppl (20 de mayo de 2012): 2552. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.2552.
Texto completoIwamoto, Mitsuhiko, Nayuko Sato, Risa Terasawa, Hiroya Fujioka, Yuko Takahashi, Kosei Kimura, Satoru Tanaka y Kazuhisa Uchiyama. "Phase II study of eribulin mesylate as first- or second-line therapy for metastatic HER2-negative breast cancer." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): TPS1140. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.tps1140.
Texto completoRaftopoulos, Harry, Joseph Aisner, Kirushna Kumar, Sanjay Goel, Christian Dittrich, Minish Jain, Prashanth Gopalakrishna, Paloma Salazar, Beverley Jones y Daniel Peter Petrylak. "Phase Ib extension study of eribulin mesylate in combination with carboplatin in patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): e19145-e19145. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e19145.
Texto completoCapítulos de libros sobre el tema "Eribulin Mesylate"
Bauer, Armin. "Story of Eribulin Mesylate: Development of the Longest Drug Synthesis". En Topics in Heterocyclic Chemistry, 209–70. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/7081_2016_201.
Texto completo"Eribulin Mesylate". En ASHP® Injectable Drug Information™, 616. ASHP, 2021. http://dx.doi.org/10.37573/9781585286850.149.
Texto completoChase, Charles, Hyeong-wook Choi, Atsushi Endo, Francis Fang y John Orr. "Development and Commercialization of a Fully Synthetic Marine Natural Product Analogue, Halaven® (Eribulin Mesylate)". En Marine Biomedicine, 497–530. CRC Press, 2015. http://dx.doi.org/10.1201/b19081-21.
Texto completoActas de conferencias sobre el tema "Eribulin Mesylate"
Reyderman, Larisa, Timothy J. Carrothers, Borje Darpo y Allan Kristensen. "Abstract B193: Analysis of the concentration-QTc relationship for eribulin mesylate." En Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1535-7163.targ-11-b193.
Texto completoAlbu, Diana I., Namita Kumar, Galina Kusnetzov, Shanqin Xu, Bruce Littlefield y Mary Woodall-Jappe. "Abstract B90: Eribulin mesylate alters immune homeostasis in mice bearing syngeneic tumors." En Abstracts: AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; December 2-5, 2012; Miami, FL. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.tumimm2012-b90.
Texto completoTanriverdi, Gamze. "Evaluation of eribulin mesylate efficacy on proliferation and apoptosis of C6 Glioblastoma cells". En 15th International Congress of Histochemistry and Cytochemistry. Istanbul: LookUs Scientific, 2017. http://dx.doi.org/10.5505/2017ichc.pp-126.
Texto completoWozniak, Krystyna, Ying Wu, Kenichi Nomoto, Bruce A. Littlefield, Christopher DesJardins, Edgar Schuck, Phil Saxton, Nancy Wong y Barbara S. Slusher. "Abstract 4653: Pharmacokinetics and biodistribution of eribulin mesylate, paclitaxel, and ixabepilone in mouse". En Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-4653.
Texto completoWozniak, Krystyna, Ying Wu, Bruce A. Littlefield, Kenichi Nomoto, Christopher DesJardins, Yanke Yu, George Lai, Larisa Reyderman y Barbara S. Slusher. "Abstract 4503: Pharmacokinetics and pharmacodynamic analysis of eribulin mesylate and paclitaxel in mouse". En Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4503.
Texto completoAsano, Makoto, Kenji Hyodo, Yanke Yu, Edgar Schuck, Junji Matsui, Hiroshi Ishihara, Hiroshi Kikuchi y Kenichi Nomoto. "Abstract 4543: Characterization of the liposomal formulation of eribulin mesylate (E7389) in mice". En Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4543.
Texto completoAlbu, Diana I., Bruce A. Littlefield y Mary Woodall-Jappe. "Abstract 1227: Macrophage depletion enhances the anticancer efficacy of eribulin mesylate in mice bearing syngeneic tumors." En Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-1227.
Texto completoUtsumi, T., T. Hayashi, N. Kobayashi, M. Hikichi, K. Ushimado, Y. Ri, S. Nakano, K. Fujii y T. Ando. "Abstract P5-15-10: Eribulin mesylate (eribulin) showed inhibitory effects on epithelial-mesenchymal transition (EMT) in tumors of metastatic breast cancer patients. -First preliminary report of a prospective study-". En Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-p5-15-10.
Texto completoMeattini, Icro, Vieri Scotti, Carla De Luca Cardillo, Beatrice Detti, Vanessa Di Cataldo y Lorenzo Livi. "Abstract P1-15-21: Safety of eribulin mesylate and concomitant palliative radiotherapy for metastatic breast cancer: A single-center experience". En Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p1-15-21.
Texto completoSchwartzberg, Lee, Kristi McIntyre, Joyce O'Shaughnessy, Stefan Glück, Erhan Berrak, James Song, David Cox y Linda Vahdat. "Abstract P5-17-02: Quality of life in patients receiving first-line eribulin mesylate for HER2- locally recurrent or MBC". En Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p5-17-02.
Texto completo